Fructose catabolism starts with phosphorylation of d-fructose to fructose 1-phosphate, which
is performed by ketohexokinase (KHK). Fructose metabolism may be the key to understand …

A series of indazoles have been discovered as KHK inhibitors from a pyrazole hit identified
through fragment-based drug discovery (FBDD). The optimization process guided by both X …

Abstract The 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase-3 (PFKFB3) is a
master regulator of glycolysis in cancer cells by synthesizing fructose-2, 6-bisphosphate (F …

Increased fructose consumption and its subsequent metabolism have been implicated in
metabolic disorders such as nonalcoholic fatty liver disease and steatohepatitis …

Glycogen synthase kinase-3 (GSK-3), a serine/threonine kinase, is a fascinating enzyme
with diverse biological actions in intracellular signaling systems, making it an emerging …

Diabetes mellitus (DM) is a chronic metabolic disease, the third killer of mankind. The finding
of potent drugs against diabetes remains challenging. In the present study, coumarin …

Background: Hexokinase 2 (HKII) is a rate-limiting and the first key enzyme of glycolysis,
responsible for the biosynthesis of glucose-6-phospate (G6P) and is up-regulated in dengue …

Abstract Glycogen synthase kinase 3 (GSK-3) is involved in different diseases, such as
manic-depressive illness, Alzheimer's disease and cancer. Studies have shown that insulin …

Inhibitors of ketohexokinase (KHK) have potential for the treatment of diabetes and obesity.
We have continued studies on a pyrimidinopyrimidine series of potent KHK inhibitors by …

The α-glucosidase inhibitors are considered as important agents in drug discovery against
diabetes mellitus. Molecular docking and quantitative structure-activity relationship (QSAR) …